🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. CAR-T Cells

    The First People's Hospital of Lianyungang

    Lung Neoplasm Malignant

    phase 2 mab active

    1 trial

  2. CAR-T treatment

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 2 mab active

    1 trial

  3. CART infusion

    Hospital Authority, Hong Kong

    B-cell Lymphoma Refractory

    phase 2 other active

    1 trial

  4. CD19 CAR T-Cell(CAT19T2)

    Zhujiang Hospital

    B-cell Acute Lymphoblastic Leukemia

    phase 2 mab terminated

    1 trial

  5. CD19 CAR-T cells

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  6. CD19 CAR-T cells and CD19 positive feeder T cells

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia in Remission

    phase 2 mab active

    1 trial

  7. CD19 or CD20 CAR T cells briging HSCT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, Large B-Cell, Diffuse

    phase 2 mab active

    1 trial

  8. CD19X CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Large B-Cell Lymphoma (LBCL)

    phase 2 small molecule active

    1 trial

  9. CD22/CD19 CAR T and auto-HSCT "sandwich" strategy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Acute Lymphoblastic Leukemia

    phase 2 other active

    1 trial

  10. CD25 antibody combined glucocorticoid as first-line treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Graft Versus Host Disease

    phase 2 small molecule active

    1 trial

  11. CHOP+selinexor+5-Azacitidine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Peripheral T Cell Lymphoma

    phase 2 small molecule active

    1 trial

  12. CIK

    The First People's Hospital of Lianyungang

    Lung Adenocarcinoma

    phase 2 mab terminated

    1 trial

  13. CM313 (SC)

    The First People's Hospital of Lianyungang

    Pemphigus Disease

    phase 2 small molecule active

    1 trial

  14. CM313 Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    2 trials

  15. CM336 Injection

    The First People's Hospital of Lianyungang

    Autoimmune Bullous Disease

    phase 2 mab active

    1 trial

  16. CM336 Plus Isatuximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma (MM)

    phase 2 small molecule active

    1 trial

  17. CMOP±R

    The First People's Hospital of Lianyungang

    NHL

    phase 2 small molecule active

    1 trial

  18. CNCT19

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Large B-cell Lymphoma

    phase 2 mab completed

    1 trial

  19. Cabazitaxel Accord 20 mg/ml concentrate for solution for infusion, Lutathera 370 MBq/mL solution for infusion, Xofigo 1100 kBq/mL solution for injection, Lynparza 150 mg film-coated tablets, Docetaxel Aurovitas 20 mg/ml concentrado para solución para perfusión, BAY 1841788

    Ningbo Cancer Hospital

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  20. Cabozantinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  21. Cadonilimab

    The First People's Hospital of Lianyungang

    Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  22. Cadonilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  23. Cadonilimab

    The First People's Hospital of Lianyungang

    Immunotherapy

    phase 2 small molecule active

    1 trial

  24. Cadonilimab

    Second Affiliated Hospital of Soochow University

    Immunotherapy

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources